If you are searching for clear information on GLP-1 access in New Zealand, the short answer is this: Ozempic (semaglutide) and Mounjaro (tirzepatide) are both available, Wegovy (the higher-dose semaglutide approved specifically for weight management) has been intermittently supplied, Pharmac funding is currently focused on type 2 diabetes rather than weight loss, and most weight-management prescriptions in NZ are private and out-of-pocket at several hundred to over a thousand dollars per month depending on dose and supply. This article walks through the access pathways, the cost reality, and the questions worth asking your GP. None of this is medical advice. Prescribing decisions are between you and your doctor.
What is currently available
Three GLP-1 medications matter for the NZ conversation right now: Ozempic (semaglutide, weekly injection), Mounjaro (tirzepatide, a dual GIP/GLP-1 agonist, weekly injection), and Wegovy (the higher-dose semaglutide approved specifically for weight management). Ozempic and Mounjaro have been the more reliably supplied options. Wegovy supply in NZ has been intermittent. Saxenda (liraglutide, daily injection) sits in the same class but has largely been overtaken in clinical use by the weekly options. Newer compounds are in the pipeline overseas and will reach NZ on their own timelines.
Medsafe is the source of truth for what is actually approved here, the indications it is approved for, and the data sheets covering dosing and safety. Always check the current data sheet rather than trusting a secondary source, including this one. Approval status and supply both move.
Pharmac funding: the current picture
As of April 2026, Pharmac funding for the GLP-1 class is directed at type 2 diabetes management, not weight management. People who have type 2 diabetes and meet the funding criteria can access a funded prescription via their GP. Everyone else, including those who would clinically benefit from a GLP-1 for weight loss, is paying privately.
There is an active advocacy and policy conversation about extending funding to weight management given the cardiovascular and metabolic upside. That picture may shift. The practical position today is that if your prescription is for weight loss rather than diabetes, expect to pay out of pocket. Confirm the current criteria with your GP and check Pharmac's published schedule rather than relying on assumptions.
Private prescription: what it actually costs
As of April 2026, private monthly cost in NZ has typically sat in the several-hundred to over-a-thousand-dollar range, depending on the medication, the dose, and pharmacy supply at the time. Cost rises as the dose escalates through the titration schedule. A starting dose is cheaper than a maintenance dose. Most people are on the medication for many months, often more than a year, so the realistic budgeting horizon is the cumulative cost across the planned duration, not just the first month.
Compounded versions exist in some markets. In NZ the safer, more predictable path is the branded, Medsafe-approved product through a registered pharmacy. Pricing moves with supply and exchange rates, so get current figures from your prescribing GP and pharmacy before committing.
The honest framing: this is a sustained financial commitment. If the budget cannot support twelve months at the realistic cost, it is worth having that conversation upfront rather than starting and stopping.
Access pathways
The standard pathway in NZ is your GP. They hold your full medical history, can screen for contraindications, can manage interactions with existing medications, and can coordinate ongoing monitoring. Starting there is almost always the right move.
Specialist referral, typically to endocrinology or obesity medicine, is appropriate where there is clinical complexity, multiple conditions interacting, or where your GP wants additional input before prescribing. The wait and cost vary.
Tele-prescribing services have emerged in NZ. Convenience is the trade-off against continuity of care: a remote prescriber does not have the long view of your health, may not coordinate with the rest of your care team, and the regulatory landscape is still settling. If you go this route, be deliberate about keeping your GP in the loop.
The conversation to have with your GP
Walk in with specific questions rather than a request. Useful ground to cover:
- Contraindications relevant to your history. Personal or family history of medullary thyroid carcinoma, MEN2, severe gastrointestinal disease, pancreatitis history, and pregnancy or planned pregnancy all matter.
- Interactions with anything you are currently taking. Insulin or sulfonylureas in particular need active management.
- The titration schedule and what to expect at each step.
- Side effects that are common, side effects that warrant a call back, and side effects that warrant stopping.
- Monitoring requirements: weight, blood pressure, lipids, HbA1c if relevant.
- Realistic expectations on weight change over six to twelve months.
- What lean mass protection looks like alongside the medication and whether nutrition and resistance training support is in place.
- The exit plan. What happens at the end and how it is managed.
The medication is one input. The plan around it is what determines whether the result holds.
Side effects and what to plan for
The common ones are gastrointestinal: nausea, reflux, constipation, sometimes vomiting, particularly during titration. For most people they ease as the body adjusts and as the dose stabilises. A subset find them sustained enough that the medication is not viable.
Reduced appetite is the mechanism that does the work. Eating less feels easier because hunger signals soften. That is the lever. The risk is that "eating less" without intent defaults to eating less of everything, including protein. Lean mass loss alongside fat loss is the dominant nutrition risk on a GLP-1 and the one we see clinically when people arrive without a plan. The body composition outcome is determined by how this is managed. Reference: GLP-1 and muscle mass preservation.
Other less common but documented effects include gallbladder issues, injection-site reactions, and rare cases of pancreatitis. Your GP and the data sheet are the source of truth on the full profile.
Why the nutrition strategy matters more than the medication choice
The medication creates a window of reduced appetite. Nutrition determines what happens in that window. Choose Ozempic or Mounjaro and the macro question is the same: hit a protein target high enough to defend lean mass while in a calorie deficit, structure meals around that, and pair the eating pattern with resistance training. Get that right and the weight that comes off is mostly fat. Get it wrong and a meaningful portion is muscle, which sets up the rebound problem.
This is also why we describe ourselves as medication-agnostic. The strategy that protects body composition is consistent across the GLP-1 options. The choice between them is a clinical decision your GP makes. Reference: GLP-1 nutrition strategy and GLP-1 rebound effect.
Life after GLP-1
The harder period is after the medication, not during it. Once appetite returns to baseline, the eating patterns set during treatment get tested. Most regain happens here, and the predictor is whether the maintenance habits were deliberately built during the medicated phase or whether they were a function of suppressed hunger.
The protocol that prevents this is straightforward to describe and takes effort to execute: maintain the protein anchor, hold the training volume, transition off the medication on a planned taper rather than a sudden stop, and run a structured maintenance phase where the new body composition is held and tested at maintenance calories before any other goal is layered on. This is where coaching adds the most value over time. The first six months post-medication is the make-or-break window.
How Inception Nutrition supports GLP-1 clients
We are medication-agnostic. We do not recommend or advise on which GLP-1 to take, nor on dose, escalation, or discontinuation. That is your GP's remit. What we do is build the nutrition and training programme alongside the medication so the weight loss is composed mostly of fat rather than lean mass, the dietary habits set during treatment hold after it, and the body composition outcome is durable.
The starting point is the Free Metabolic Audit or a direct enquiry through Coaching. For a deeper read on how GLP-1s actually work, see How GLP-1 agonists work.
